Bristol-Myers Squibb: Non-alcoholic Fatty Liver Disease trials
The registry lists 10 Non-alcoholic Fatty Liver Disease studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 7 have results posted.
Phase 1 4Phase 2 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)TerminatedNCT04267393Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver FibrosisTerminatedNCT04048876Phase 2Results posted
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver CirrhosisCompletedNCT03486912Phase 2Results posted
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver FibrosisCompletedNCT03486899Phase 2Results posted
- A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT03400163Phase 2Results posted
- A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious PsoriasisTerminatedNCT03329885Phase 1/2Results posted
- A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)CompletedNCT02413372Phase 2Results posted
- A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver DiseaseTerminatedNCT04766476Phase 1
- An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney FunctionCompletedNCT03674476Phase 1
- A Study of Experimental Medication BMS-986036 Given to Healthy ParticipantsCompletedNCT03445208Phase 1